IndicationPreclinicalEarly-Stage ClinicalLate-Stage ClinicalRegulatory Submission
Relapsed/Refractory EBV+ Lymphoma

Relapsed/Refractory EBV+ Solid Tumors

Other Virus-associated Malignancies

Relapsed/Refractory EBV+ Lymphoma Late-Stage Clinical
Relapsed/Refractory EBV+ Solid Tumors Early-Stage Clinical
Other Virus-associated Malignancies Preclinical

Regulatory Status

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.

    Orphan Drug Designations granted for nanatinostat with valganciclovir for the treatment of:
  • T-cell lymphoma
  • Post-transplant lymphoproliferative disorder (PTLD)
  • Plasmablastic lymphoma

Viracta has initiated a clinical trial to treat EBV+ lymphomas. For more information about the trial, see ClinicalTrials.gov.
Contact: clinicaltrials@viracta.com

Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.